Related Experiment Video
Updated: Jul 11, 2026
03:25
Simple Continuous Glucose Monitoring in Freely Moving Mice
Published on: February 24, 2023
Continuous glucose monitors: the long-awaited watch dogs?
I M E Wentholt1, J B L Hoekstra, J H Devries
1Department of Internal Medicine, Academic Medical Center, Amsterdam, the Netherlands. I.M.Wentholt@amc.uva.nl
Diabetes Technology & Therapeutics
|October 13, 2007
Summary
Continuous glucose monitors (CGMs) show promise for diabetes care but require more controlled studies. Increased accuracy and reimbursement are crucial for widespread adoption of these glucose monitoring devices.
Area of Science:
- Endocrinology
- Medical Devices
- Diabetes Technology
Background:
- Several continuous glucose monitors (CGMs) are available, but widespread use in standard diabetes care is limited.
- Understanding the clinical applications and relevant aspects of CGMs is essential.
Purpose of the Study:
- To provide an overview of current applications and clinically relevant aspects of continuous glucose monitors (CGMs).
- To discuss calibration, data interpretation, and limitations of CGMs.
- To assess the impact of CGMs on glycemic control and patient outcomes.
Main Methods:
- Review of current literature on continuous glucose monitors.
- Analysis of calibration procedures and interpretation of continuous glucose data.
- Evaluation of existing studies on CGM efficacy and limitations.
Main Results:
- Evidence for significant improvement in glycemic control (e.g., HbA1c, hypoglycemia) with CGMs is limited, particularly from controlled studies.
- Non-controlled trials suggest a positive trend in glycemic control.
- Key limitations and challenges for CGM implementation were identified.
Conclusions:
- More controlled trials are needed to definitively establish the benefits of CGMs for glycemic control in type 1 diabetes.
- Future research should include patient-reported outcomes like health status and treatment satisfaction.
- Enhanced accuracy and improved reimbursement policies are critical for broader CGM adoption.
Related Concept Videos
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
01:02Glucose Homeostasis: Regulation of Blood Glucose
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...